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Hyperglycemia is a common problem encountered in hospitalized patients,
especially in critically ill patients and those with diabetes mellitus.
Uncontrolled hyperglycemia may be associated with complications such as
fluid and electrolyte disturbances and increased infection risk.  Studies have
demonstrated impairment of host defenses, including decreased poly-
morphonuclear leukocyte mobilization, chemotaxis, and phagocytic activity
related to hyperglycemia.  Until 2001, hyperglycemia (blood glucose
concentrations up to 220 mg/dl) had been tolerated in critically ill patients
not only because high blood glucose concentrations were believed to be a
normal physiologic reaction in stressed patients and excess glucose is
necessary to support the energy needs of glucose-dependent organs, but also
because the true significance of short-term hyperglycemia was not known.
Recent clinical data show that the use of intensive insulin therapy to maintain
tight blood glucose concentrations between 80 and 110 mg/dl decreases
morbidity and mortality in critically ill surgical patients.  Intensive insulin
therapy minimizes derangements in normal host defense mechanisms and
modulates release of inflammatory mediators.  The principal benefit of
intensive insulin therapy is a decrease in infection-related complications and
mortality.  Further research will define which patient populations will benefit
most from intensive insulin therapy and firmly establish the blood glucose
concentration at which benefits will be realized.
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Hyperglycemia is a common problem encoun-
tered in hospitalized patients, especially in
critically ill patients and those with diabetes
mellitus.  Risk of hyperglycemia is increased in
patients receiving concentrated dextrose infusions
such as parenteral nutrition.  Uncontrolled
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hyperglycemia may be associated with compli-
cations such as fluid and electrolyte disturbances
and increased infection risk.  Controlling
hyperglycemia reduces microvascular and
macrovascular complications in patients with
diabetes1–6 and reduces nosocomial and wound
infections in perioperative hyperglycemic and
diabetic patients.7–16 However, a cause and effect
relationship between sepsis and hyperglycemia
has long been debated.  Although it has been
clearly documented that sepsis induces
hyperglycemia, the effects of hyperglycemia on
increasing infection risk had not been fully
elucidated.17 Until 2001, blood glucose concen-
trations up to 220 mg/dl had been tolerated in
critically ill patients.18, 19 This was essentially
based on the belief that high blood glucose
concentrations were a normal physiologic
reaction in stressed patients, and excess glucose
was necessary to support the energy needs of
glucose-dependent organs such as the brain,
adrenal medulla, and red blood cells.  However,
recent data show that the use of intensive insulin
therapy to maintain tight blood glucose concen-
trations between 80 and 110 mg/dl decreases
morbidity and mortality in critically ill surgical
patients.  The benefits of tight glucose control
also extend to significant reductions in several
morbidity factors including infection rate.20
Normal Glucose Metabolism
Glucose metabolism involves complex metabolic
reactions to maintain glucose homeostasis.
Exogenous glucose sources include dietary
carbohydrates or dextrose infusions.  Endogenous
glucose sources include glycogen stores that
release glucose through liver glycogenolysis and
from noncarbohydrate precursors (e.g., lactate,
alanine, glycerol) that are converted to glucose
through gluconeogenesis mainly in the liver and
to a lesser extent in the kidneys.  The brain, red
blood cells, and renal medulla depend on glucose
for energy by non–insulin-mediated uptake
mechanisms.21 Under basal conditions, these
glucose-dependent tissues consume about
50–80% of ingested glucose.22, 23 The remaining
glucose is converted to produce energy through
glycolysis, stored as glycogen in the liver and
skeletal muscles, or converted to fat in the liver
and adipose tissues.22, 23
Blood glucose concentrations are controlled by
hormonal, neural, and hepatic autoregulatory
mechanisms.  In a healthy individual, blood
glucose concentrations are tightly regulated
within a narrow range of about 80–100 mg/dl.
Hormonal mechanisms are exerted by insulin and
the counterregulatory hormones, which include
glucagon, catecholamines, cortisol, and growth
hormone.  Effects of insulin are exerted mainly
through its anabolic function to increase glucose
uptake and storage.21, 24 Insulin effects are also
mediated through its antiinflammatory sup-
pression of proinflammatory cytokine (e.g.,
tumor necrosis factor-a, interleukin [IL]-1, and
IL-6) production and signaling25–28 to lower
blood glucose concentrations by stimulating
glucose uptake and glycogen synthesis, and
inhibiting glyconeogenesis.21, 22, 24, 29
Counteracting the anabolic effects of insulin
are the counterregulatory hormones that stimulate
glycogenolysis and gluconeogenesis and inhibit
insulin-mediated glucose uptake.21–23 Neural
mechanisms involve central and peripheral
glucosensors that monitor glucose availability
and respond to changes in blood glucose concen-
tration by releasing insulin or inhibiting insulin
secretion.  Hepatic autoregulation responds
directly to increased blood glucose concentration
by decreasing its glucose production.22
Glucose Metabolism in Critical Illness
Significant alterations to glucose metabolism
occur under conditions of stress such as trauma,
burn, major surgery, and sepsis.  Stress-induced
hyperglycemia is the result of increased
sympathomimetic activity and increased release
of counterregulatory hormones and proinflam-
matory cytokines.  Counterregulatory hormones
enhance glycogenolysis and gluconeogenesis to
increase glucose production.  For instance,
epinephrine enhances glycogenolysis in the liver
and skeletal muscles and increases gluconeo-
genesis in the kidneys.  Growth hormone inhibits
peripheral glucose uptake and stimulates
gluconeogenesis.  Proinflammatory cytokines are
inflammatory mediators that also contribute to
increasing glucose production by stimulating
gluconeogenesis and glycogenolysis and by
indirectly increasing the release of counter-
regulatory hormones such as glucagon and
cortisol.  Furthermore, proinflammatory cytokines
contribute to insulin resistance by inhibiting
insulin release.  The end result of these physio-
logic changes is increased endogenous glucose
production coupled with insulin resistance that
leads to stress-induced hyperglycemia.21–23, 30, 31
Patients receiving dextrose infusions, especially
those administered as part of parenteral nutrition,
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are at highest risk for developing hyperglycemia.
However, other risk factors also predispose patients
to hyperglycemia; these include underlying con-
ditions such as diabetes mellitus, acute pancreatitis,
and obesity, as well as drugs such as catecholamine
vasopressors (e.g., dopamine, norepinephrine),
immunosuppressants (e.g., tacrolimus, cyclo-
sporine), and corticosteroids17 (Figure 1).
Hyperglycemia
Definition
The definition of diabetic hyperglycemia was
most recently revised in 1997 by the Expert
Committee on Diagnosis and Classification of
Diabetes Mellitus:  diabetic hyperglycemia is
diagnosed based on symptoms of diabetes and a
random plasma blood glucose concentration
higher than 200 mg/dl, a fasting blood glucose
concentration of 126 mg/dl or higher, or a 2-hour
post-load blood glucose concentration higher
than 200 mg/dl.32 As previously stated, however,
hyperglycemia in the critically ill patient is less
clearly defined, and the notion of the beneficial
effects of hyperglycemia is being challenged now
in view of better patient outcomes with tighter
glucose control to maintain euglycemia.20
Complications
In patients with diabetes, uncontrolled blood
glucose concentration is associated with increased
occurrence of microvascular complications (e.g.,
retinopathy, nephropathy, peripheral neuropathy)
and macrovascular complications (e.g., athero-
sclerotic cardiovascular, peripheral vascular, and
cerebrovascular diseases).1–6, 19, 32 Hyperglycemia
also leads to multiple adverse consequences
including osmotic diuresis, fluid and electrolyte
imbalances, hyperosmolar nonketotic coma,
worsening skeletal muscle catabolism, impaired
wound healing, changes in coagulability, impaired
immune function, increased susceptibility to
infections,22, 30, 33 and death in certain surgical
patients.34
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Figure 1. Causes of hyperglycemia and effects of hyperglycemia on increased susceptibility to infection in the critically ill
patient.  aCounterregulatory hormones are glucagon, catecholamines, cortisol, and growth hormone; bproinflammatory
cytokines are tumor necrosis factor-a, interleukin (IL)-1, and IL-6.
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Pathogenesis of Hyperglycemia-Associated
Infection
A rise in the risk of postoperative infectious
complications results from depressed immune
function secondary to inhibition of IL-1 release
from macrophages, impaired phagocytosis, and
diminished production of oxygen radicals from
neutrophils.21, 35 As a result, studies addressed
the effect of transient acute hyperglycemia in a
nondiabetic rat model on immune function after
surgery36 or splenectomy.37 The authors of the
first study evaluated the function of peripheral
neutrophils, peritoneal macrophages, and
alveolar macrophages in postoperative nondiabetic
rats in two groups:  normoglycemic (control) and
hyperglycemic.36 Their results showed significant
change in immune function based on blood
glucose concentration.
The second study focused on demonstrating
decreased immunologic activity in rats after
splenectomy and induction of bacteremia in the
setting of hyperglycemia.37 Survival times were
markedly lower in the hyperglycemic group.
Consequently, the authors concluded that short-
term exposure to high glucose concentration has
detrimental effects to the immune function of the
studied cells and could be one of the primary
factors contributing to increased susceptibility to
infection in this population.  Furthermore, the
effect of blood glucose control with exogenous
insulin was determined in vivo in a study of
rabbits with severe injury.27 Results revealed
improvement in phagocytosis and oxidative
killing with prevention of weight loss, hypona-
tremia, lactic acidosis, and excessive inflam-
mation in the group maintained at normo-
glycemia (60–110 mg/dl).  Similar findings came
from an in vitro study that showed significant
reduction in polymorphonuclear leukocyte
phagocytic activity of normal cells in intermittent
hyperglycemia compared with control.38
Hyperglycemia and Infection in Patients with
Diabetes
Blood glucose control was originally
investigated in the setting of diabetes because
diabetic patients seemed to be predisposed to
various infections (e.g., cystitis, cellulitis,
postoperative wound infections10) and infectious
complications as a result of having diabetes.39
Although the exact pathogenesis was unknown,
it was speculated that the increased risk of
infection was related to decreased cellular
immune function.10 Later studies (both in
animals and humans) demonstrated that the
depressed ability to fight off infection was a result
of impaired polymorphonuclear leukocyte
function, chemotaxis, and phagocytosis.31, 39–43
Studies in diabetic animals examined the
phagocytic activity44 and membrane fluidity45 of
certain immune cell types.  Results showed
impaired intracellular killing44 and higher
susceptibility to infection although decreased
fluidity45 in animals with poorly controlled
diabetes compared with well-controlled ones.  In
vitro studies in diabetic patients further
strengthened the evidence of cellular immune
function impairment by demonstrating a
significant reduction in polymorphonuclear
leukocyte mobilization, chemotaxis, and
bactericidal and phagocytic activity in poorly
controlled42, 46 diabetic cells compared with well-
controlled ones42, 46 and diabetic47 cells in general
compared with control.47 Data derived from
animal and in vitro trials led to further investi-
gation of the link between hyperglycemia and
infectious complications in patients with
diabetes.
In 1991, one group of authors performed a
retrospective chart review to compare operative
mortality and complications (e.g., wound
infections, myocardial infarction, arrhythmias,
respiratory failure) in diabetic versus nondiabetic
patients after coronary artery bypass graft
(CABG).7 Their analysis included 711 patients,
79% nondiabetic and 21% diabetic.  The results
did not show a difference between the two
groups with respect to mortality but demon-
strated a significantly increased morbidity in the
diabetic group especially in the wound infection
parameter.
Another group looked specifically at the rate of
deep sternal wound infections in diabetic
patients after cardiac surgery in a before and after
retrospective chart review.8 A strict blood glucose
control protocol was implemented, with a target
of blood glucose concentration less than 200
mg/dl.  A total of 999 patients had surgery before
the protocol was implemented, and 595 had
surgery after.  The results revealed a significant
reduction in deep wound infection after protocol
implementation, with elevated blood glucose
level being directly related to infection rate.
Later, these authors further demonstrated that
the use of perioperative continuous intravenous
infusion in this patient population significantly
reduced morbidity from deep sternal wound
infections and the costs associated with it.11
An increased rate of nosocomial infection in
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diabetic patients undergoing elective surgery was
demonstrated in 1998.  This was a noninter-
ventional study with the objective to determine
the relationship between perioperative glucose
control (good blood glucose level was defined as
< 220 mg/dl) and postoperative infection rate.9
Analysis of 93 patients and their serum glucose
concentrations on postoperative day 1 indicated
that the nosocomial infection rate was 2.7 times
higher in diabetic patients with a blood glucose
level above 220 mg/dl and 5.7 times higher when
urinary tract infections were eliminated
compared with patients with better glucose
control.  Thus, these authors concluded that a
blood glucose level above 220 mg/dl was a
sensitive predictor (87.5%) of nosocomial
infection.
Finally, in 1999, another group performed a
nonconcurrent, prospective, cohort, blinded
study with the purpose of assessing the
independent relationship between perioperative
glycemic control and subsequent risk of
infectious complications (e.g., pneumonia,
urinary tract infection, wound infection) on
postoperative day 2 or later in diabetic patients
undergoing coronary artery surgery.10 Their
results echoed those of the previous studies and
showed an increased infection rate in patients
with a perioperative blood glucose level higher
than 200 mg/dl.  There was no relationship
between peak perioperative blood glucose level
and subsequent risk of infectious complications.
Table 1 summarizes the studies relating hyper-
glycemia with infection and mortality in the
surgical and critically ill patient population.
Hyperglycemia and Infection in Critically Ill
Patients
As evidence accumulated in support of tight
glycemic control in patients with diabetes, there
still remained significant controversy regarding
the pathophysiology and management of stress-
induced hyperglycemia.  Increased glucose
turnover and insulin resistance were regarded as
potentially appropriate responses during critical
illness.22 Also, although the association between
hyperglycemia and infection had been well
established,31 debate continued regarding which
condition precipitated the other.51 However, data
are now emerging that provide important
information on the consequences and manage-
ment of hyperglycemia in critically ill patients.20
In 2001, a group of authors published the
results of a large, prospective, randomized,
controlled trial that was the first to challenge the
accepted clinical practice of loose glycemic
control in critically ill patients.20 During a 1-year
period, 1548 patients with mechanical ventilation
who were admitted to an intensive care unit
(ICU) after surgery or trauma were randomly
assigned to either intensive insulin or conven-
tional therapy.  The conventional therapy group
was targeted to maintain a blood glucose level of
180–200 mg/dl with insulin therapy to begin at a
blood glucose level higher than 215 mg/dl, with
the insulin dose adjusted by the nursing staff.
The intensive insulin therapy group was targeted
to maintain a blood glucose level at 80–110
mg/dl with insulin therapy to begin at a blood
glucose level higher than 110 mg/dl following a
strict algorithm.
Hypoglycemia was defined as a blood glucose
level less than 40 mg/dl.  After discharge from the
ICU, both groups were switched to subcutaneous
insulin with a target blood glucose level of less
than 200 mg/dl.  The primary outcome was all-
cause ICU mortality and secondary outcomes
included in-hospital mortality, number of ICU
and ventilation days, ICU stay longer than 14
days or readmission, use of renal replacement
therapy and inotropic or vasopressor support,
occurrence of infections, and critical illness
polyneuropathy.
Results showed that use of intensive insulin
therapy was associated with a 34% decrease in
overall in-hospital mortality.  The ICU mortality
rate decreased from 8% to 4.6% (> 40%
reduction), with the effect occurring primarily in
patients in the ICU for more than 5 days
(intensive therapy group 10.6% mortality vs
20.2% mortality in conventional therapy group).
After adjustment for repeated interim analyses,
the median unbiased estimate of mortality
reduction was 32% (adjusted 95% confidence
interval 2–55%, p<0.04).  No significant
difference was noted in mortality between the
two groups within the first 5 days in ICU.
Furthermore, tight blood glucose control
significantly decreased morbidity as demon-
strated by a reduction in the duration of
ventilatory support and ICU stay, reduced need
for blood transfusions, 46% reduction in
frequency of sepsis, decreased frequency of
excessive inflammation, 44% reduction in
polyneuropathy, and 41% reduction in acute
renal failure.  The overall conclusion was that use
of exogenous insulin to maintain a blood glucose
level below 110 mg/dl reduced morbidity and
ICU and in-hospital mortality among surgical
967
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Table 1.  Infection Rate and Mortality in Clinical Trials of Hyperglycemia and Infection in Surgical and Critically Ill Patients
Trial Design (year) Study Type Patient Population Primary End Point Results
Nonrandomized, Observational Diabetic and nondiabetic Mortality within 30 days of No difference in
retrospective patients undergoing CABG surgery or during same mortality.  Higher
(1991)7 (n=711, 146 diabetic vs hospitalization morbidity and wound
565 nondiabetic patients) infection rate in
diabetic vs nondiabetic
patients.
Prospective, Observational Diabetic patients Relationship between glucose Higher infection rate
nonrandomized, undergoing elective control and development of (except for UTI) in
cohort surgery (n=93) postoperative nosocomial patients with BGL >
(1998)9 infections (bacteremia, UTI, 220 mg/dl vs BGL <
pneumonia, surgical wound 220 mg/dl on post-
infection, intraabdominal abscess, operative day 1.
Clostridium difficile colitis)
Nonconcurrent, Observational Diabetic patients Relationship between peri- Higher overall infection
prospective, undergoing CABG operative glycemic control rate and infectious
cohort, blinded (n=411) and development of post- complications
(1999)10 operative infectious complica- corresponding to
tions (pneumonia, UTI, wound higher BGL.
infection, other) on day 2 or
≥ 36 hrs after surgery
Nonrandomized, Observational Diabetic and nondiabetic Deep sternal site infection Lower deep sternal site
retrospective, patients undergoing CABG rate before and during infection rate before vs
case-control (n=120, 30 case patients study period during study period.
(2000)12 with deep sternal site
infection, 90 control patients)
Nonrandomized, Observational Diabetic and nondiabetic Development of radial Higher rate of radial
retrospective, patients undergoing radial artery harvest site infection artery harvest site
case-control artery graft for after CABG during infection during
(2000)13 revascularization during heightened and routine heightened vs routine
CABG (n=127, 35 case postdischarge surveillance surveillance.
patients, 92 control patients)
Prospective, Observational Patients with known DM, Development of surgical Frequency of surgical
cohort, blinded, unknown DM, and non- site infection as related site infections directly
case-control diabetic patients with to BGL control (BGL and and significantly
(2001)14 hyperglycemia undergoing hemoglobin A1c) correlated with degree
CABG or cardiac valve of hyperglycemia
procedure (n=1044, 300 during postoperative
with known DM, 700 with period.  Higher surgical
unknown DM, 44 DM status site infection rate in
not mentioned; 74 infected, patients with known
970 control) DM vs patients with
unknown DM.  Higher
surgical site infection 
rate in patients with
known and unknown
DM and nondiabetic
patients.
Retrospective, Observational Diabetic and nondiabetic Postoperative infectious Diabetic: higher
cohort patients undergoing CABG complications (deep and perioperative BGL
(2002)15 (n=1090, 400 diabetic, superficial sternal wound correlated with higher
690 nondiabetic patients) infection, donor site deep sternal wound
infection, UTI, lung infection rate.  Higher
infection) as related to postoperative infection
peri- and postoperative rate (deep sternal
glycemic control wound infection,
donor site infection,
UTI) in diabetic vs
nondiabetic patients.
Higher early mortality
in diabetic vs
nondiabetic patients.
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critically ill patients regardless of their history of
diabetes.
This study demonstrated that tight glycemic
control can prevent infections and associated
complications in critically ill surgical patients.
Sixty-one patients (7.8%) developed sepsis
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Table 1.  Infection Rate and Mortality in Clinical Trials of Hyperglycemia and Infection in Surgical and Critically Ill Patients
(continued)
Trial Design (year) Study Type Patient Population Primary End Point Results
Historic cohort Observational Diabetic and nondiabetic 30-day mortality, 30-day Higher overall
(2003)16 patients undergoing CABG infections (harvest site, infection rate in
(n=1574, 545 diabetic, sepsis, pneumonia, UTI, diabetic vs
1029 nondiabetic patients) deep sternal wound nondiabetics patients.
infection), resource Higher mortality in
utilization as related to patients who
perioperative developed infection
hyperglycemia in both groups.
Prospective, Observational Diabetic and nondiabetic ICU mortality In all glucose bands,
one center patients admitted to increased insulin
(2003)48 cardiothoracic, cardio- administration
respiratory surgery and corresponded with
medicine ICU (n=523) significantly increased
risk of ICU death.
Retrospective, Observational Diabetic and nondiabetic Hospital mortality Higher BGL
longitudinal, patients admitted to general corresponded with
one center medical, surgical, and higher hospital
(2003)49 coronary ICU (n=1826) mortality.
Nonrandomized, Interventional; Diabetic and nondiabetic Deep sternal wound Diabetic: higher deep
retrospective insulin patients undergoing cardiac infection rate before and sternal wound
(1997)8 protocol: surgery (n=8910, 1585 after diabetic protocol infection rate before vs
BGL goal diabetic, 7325 nondiabetic after protocol.
< 200 mg/dl patients) Nondiabetic: higher
deep sternal wound
infection rate before vs
after protocol.
Nonrandomized, Interventional; Diabetic patients undergoing Infection (deep and Higher deep sternal
prospective insulin open-heart surgery superficial sternal wound wound infection rate in
(1999)11 protocol: (n=2467, 968 control, 1499 infection, donor site control vs continuous
BGL goal continuous insulin infusion) infection) rate as related to insulin infusion group.
150–200 postoperative BGL before
mg/dl and after protocol
Prospective, Interventional; Diabetic and nondiabetic Death from any cause Lower overall ICU
randomized, insulin surgical ICU patients during ICU stay mortality, lower
controlled protocol: (n=1548, 765 intensive mortality in patients in
(2001)20 intensive insulin, 783 conventional ICU > 5 days, lower
group insulin) overall in-hospital
BGL goal mortality, lower
80–110 mg/dl; in-hospital mortality
conventional in patients in ICU
group: BGL > 5 days, lower 
goal 180–200 frequency of 
mg/dl septicemia, prolonged
antibiotics, and
bacteremia in intensive 
vs conventional group.
Nonrandomized, Interventional; Diabetic and nondiabetic In-hospital mortality before Lower hospital
historic control insulin surgical and medical ICU and after protocol mortality after protocol
(2004)50 protocol: BGL patients (n=1600, 800 implementation.
goal ≤ 140 historic control, 800 Infection rate similar
mg/dl treatment group) before and after
protocol.
CABG = coronary arterial bypass graft; BGL = blood glucose level; UTI = urinary tract infection; DM = diabetes mellitus; ICU = intensive care
unit.
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(bacteremia with systemic inflammatory response
syndrome) in the conventional therapy group
compared with 32 patients (4.2%) in the
intensive insulin therapy group (p<0.003).  In
addition to the decrease in the frequency of
septicemia, mortality from multiorgan failure
with a proven septic focus decreased from 4.2%
to 1.0%.  Indeed, this subgroup represented the
patient population that had the greatest
reduction in death with intensive insulin therapy.
Further, patients in the intensive insulin therapy
group were less likely to receive prolonged
antibiotics.  One hundred thirty-four patients
(17.1%) received antibiotics for more than 10
days in the conventional therapy group compared
with 86 patients (11.2%) in the intensive insulin
therapy group (p<0.001).
In 2003, the same group of authors addressed
the issue of the relative impact of insulin dosage
versus blood glucose concentration and their
contributions to the demonstrated outcome
benefits.25, 26 Results showed that control of
hyperglycemia, rather than dosage of insulin, was
associated with the beneficial outcomes of
decreases in mortality, bacteremia, polyneuro-
pathy, inflammation, and anemia, but not to the
prevention of acute renal failure.  The data also
showed that there was no specific threshold
below which no further risk reduction occurred.
When patients were stratified according to
glucose concentration, even moderate hyper-
glycemia (110–150 mg/dl) was associated with
significantly increased risk of bacteremia and
mortality.  The authors speculated that the
association of insulin dosage with prevention of
renal failure may be due to either a renal
protective effect of insulin or reduced insulin
requirements secondary to either increased
glucose removal in patients receiving continuous
renal replacement therapy or reduced insulin
clearance in renal failure.
In 2003, the results were published of a 6-
month, prospective, single center, observational
study evaluating glucose control and mortality
risk in 523 adult patients in the ICU.49 The goals
of the study were to determine whether control
of glucose metabolism or the degree of insulin
administration was most likely to influence
patient outcome and if there is a threshold
glucose level above which there is an increased
risk of death.  Patients were predominantly male
(72.8%) with a mean age of 64 years.  Most
subjects were cardiac surgery patients (85.1%),
with a small subset of medical patients (11.7%).
Investigators defined six different bands of
glycemic control and determined the amount of
time each patient spent within each band.  Blood
glucose results were stratified based on ICU
survival.  Results showed that increased adminis-
tration of insulin was positively and significantly
associated with increased mortality.  The authors
concluded that glucose control rather than
administration of exogenous insulin is the pre-
dominant factor in realizing decreased mortality.
Furthermore, they observed a threshold blood
glucose level between 145 and 180 mg/dl above
which an increased risk of mortality exists.  The
authors suggest that a target blood glucose level
of less than 145 mg/dl may be adequate and
should be associated with less risk of hypo-
glycemia.  The results of this study must be
interpreted with caution because of its
noninterventional design.
In 2003, results of a retrospective study were
published in which the effect of hyperglycemia in
a heterogeneous patient population was
evaluated.48 The study, which involved 1826
critically ill medical and surgical patients, found
that increased mean serum glucose concen-
trations were associated with an increased
mortality rate.  Even modest increases in mean
serum glucose concentration were associated
with an increased rate of mortality.  Due to its
retrospective nature, this study did not allow for
definitive conclusions regarding the effects of
hyperglycemia.  However, it provided compelling
evidence for further studies into the role of
hyperglycemia in causing an increased risk of
mortality in a heterogeneous population.52
In a subsequent study, the same author
evaluated the effect of a glucose management
protocol in 800 patients compared with a historic
control group of 800 patients.50 The blood
glucose goal was 140 mg/dl or less, and the study
population included surgical and medical
critically ill patients.  Results showed that use of
the glucose protocol led to significant decreases
in hospital mortality (29.3%, p=0.002), new-
onset renal failure (75%, p=0.03), patients
requiring blood transfusions (18.7%, p=0.04),
and ICU length of stay (10.8%, p=0.01).  Despite
its nonrandomized and historic control design,
this study is important in showing mortality
benefit in a heterogeneous critically ill population.
Unlike the previously mentioned 2001 study,20
this study50 showed no decrease in the frequency
of infections.  The author suggested that failure
to decrease the frequency of infection may have
been because the infection rate in the baseline
period was already low owing to multiple
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interventional policies such as antibiotic-
impregnated catheters, universal infection
precautions, and procedures for prevention of
ventilator-associated pneumonia (e.g., head of
bed elevation).  However, the level of blood
glucose control needs to be considered.  The
mean blood glucose level in the latter study52 was
130.7 mg/dl compared with the mean morning
glucose level of 103 mg/dl in the former20 study.
Post hoc analysis of the former study20 showed
that although intermediate glucose control
(110–150 mg/dl) was associated with decreased
mortality, it appeared that the benefits of
decreased morbidity, including prevention of
infections, required stricter glycemic control.26
Although the latter study50 did not achieve the
same reduction in mortality as that of the
former20 (29% vs 34%), the benefits of an insulin
infusion protocol outside of a clinical trial were
demonstrated.  In addition, episodes of hypo-
glycemia (blood glucose level < 40 mg/dl) in the
treatment groups occurred with greater frequency
in the former study20 (5.2%) than in the latter
study50 (0.34%).  However, neither study reported
clinically significant adverse outcomes in patients
who developed hypoglycemia.
Insulin Effect on Pathophysiology of
Hyperglycemia-Related Cellular Derangements
Arguing for the benefit of exogenous insulin
administration, one group of authors showed that
intensive insulin therapy exerts a powerful
antiinflammatory effect through modulation of
C-reactive protein and appears to counter the
effects of low levels of mannose-binding lectin
(MBL).53 C-reactive protein and MBL are acute-
phase proteins synthesized by the liver.  C-reactive
protein is used as an inflammatory marker, which
may be involved in the activation of leukocytes
and the complement system; MBL is involved in
innate immunity by initiating opsonization of
microorganisms.  Deficiency in MBL has been
associated with increased risk of infection.
The investigators conducted a post hoc
analysis of the subset of patients (> 5 days in the
ICU) in whom the mortality benefit of intensive
insulin therapy occurred.53 Serum C-reactive
protein and MBL were measured on admission,
days 5 and 15, and the last day of ICU stay.
Baseline serum C-reactive protein and MBL
concentrations were similar between the two
treatment groups.  Serum C-reactive protein
concentrations were significantly suppressed at
all time points in the intensive insulin therapy
group and, after day 5, were independently
associated with decreased mortality (p<0.0001)
and decreased frequency of acute renal failure
(p<0.02) by multivariate analysis.  Also, conven-
tional insulin therapy and a high baseline C-
reactive protein significantly and independently
increased the risk for prolonged inflammation
and prolonged antibiotic therapy.  For all patients,
nonsurvivors tended to have lower baseline MBL
concentrations compared with that of survivors.
In addition, a subanalysis of 243 conventionally
treated patients showed that baseline MBL
concentrations were significantly lower in
nonsurvivors compared with survivors (387 vs
897 µg/ml, p=0.04).53 During ICU stay, all
patients had significant increases in MBL
concentrations.  Although intensive insulin
therapy blunted increases in MBL concentrations
compared with conventional insulin therapy
(p<0.02), multivariate analysis showed that
insulin therapy, not baseline MBL concentrations
nor suppressed MBL concentrations over time,
determined patient outcome.  The authors
suggested that the antiinflammatory activity
associated with intensive insulin therapy partly
explains the improvement in morbidity and
mortality and that the possible adverse
consequences of low baseline MBL levels are
overcome.  Further, results showed that the
suppression of C-reactive protein was present
among uninfected survivors, thus suggesting a
direct antiinflammatory effect in the intensive
insulin therapy group.  However, the relative
contributions of glycemic control versus insulin
exposure are unknown.
The antiinflammatory effect of insulin has been
suggested also through the suppression of
proinflammatory cytokine and superoxide radical
production and signaling.26–28 Furthermore,
postulated positive effects of insulin in critical
illness include its role in the functional improve-
ment of the insulin-sensitive organs through
direct anabolic effect in acute illness, thus pro-
moting tissue repair and preventing transfusions,
dialysis, and critical illness polyneuropathy21, 24, 26,
29; enhanced energy production and delivery to
ischemic tissues; decreased free radical produc-
tion and enhanced nitric acid production; direct
anabolic effects on muscles; and maintenance of
macrophage and neutrophil function.28
Hyperglycemia and Infection in Patients
Receiving Parenteral Nutrition
Although adequate nutrition is essential to
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maintain a competent immune system,54
overfeeding and inappropriate use of parenteral
nutrition leads to serious complications.55
Compared with enterally fed patients, patients
who receive parenteral nutrition have a higher
frequency of infectious complications, which
include catheter-related sepsis, intraabdominal
abscess, wound infections, and pneumonia.56, 57
The increase in infection rate is likely the result
of several factors, including catheter-related
infections,58 reduced intestinal integrity and
immunity during bowel rest leading to bacterial
translocation,59 and the higher frequency of
hyperglycemia with parenteral nutrition.60
Patients receiving parenteral nutrition commonly
have a higher frequency of hyperglycemia and
more severe cases than those of enterally fed
patients, and this usually necessitates higher
insulin doses to achieve normoglycemia.20, 56
The Veteran Affairs Cooperative Study that
evaluated the role of perioperative parenteral
nutrition found that the benefits of this type of
nutrition are mostly in severely malnourished
patient.60 A higher frequency of postoperative
infections such as pneumonia and wound
infections occurred in mildly malnourished
patients compared with the severely malnourished
patients who received parenteral nutrition.
Although parenteral nutrition was beneficial in
malnourished patients in reducing noninfectious
complications, there was no change in infectious
complications.  A much higher frequency of
severe hyperglycemia (serum glucose concen-
trations > 300 mg/dl) occurred in patients
receiving parenteral nutrition (20%) compared
with the control group (1%).  Infection was 2.2
times more common in surgical patients who
received parenteral nutrition.  It was presumed
that severe hyperglycemia in patients who
received parenteral nutrition may have contri-
buted to increased infectious complications.61
In a meta-analysis of enteral feeding versus
parenteral nutrition studies in perioperative
patients, 61% greater infectious complications
were found in the parenteral nutrition group
compared with those who received enteral
nutrition.62 Serum glucose concentrations were
significantly higher in the parenteral nutrition
group at all points of the analysis compared with
the enteral nutrition group.  Although these two
publications60, 62 pointed at a possible correlation
between hyperglycemia and infection in patients
receiving parenteral nutrition, the relationship
between the timing of hyperglycemia and
infection and the threshold of serum glucose
concentration above which there is a higher
infectious risk were not determined.  Because
hyperglycemia may represent a response to sepsis
rather than necessarily being a cause of septic
complications, the cause-effect relationship
between hyperglycemia and infection in critically
ill patients regardless of the route of nutrition
support has been a debatable subject.63
Management of Hyperglycemia
Prevention
Prevention should be the first step in the
management of hyperglycemia.  In patients
receiving parenteral nutrition, the best approach
is to eliminate all other dextrose sources and start
with a low dextrose load and advance slowly.  A
starting dextrose infusion rate at approximately 2
mg/kg/minute (significant suppression of glucose
production occurs at 1–2 mg/kg/min64) should be
advanced to a goal of 4 mg/kg/minute or less.
These goals for dextrose administration are
derived from several clinical trials that examined
the optimum dextrose infusion rate to achieve
the best patient outcomes.65, 66
In 1979, results were published of a study of
convalescing burn patients in whom the authors
evaluated the effect of increasing rates of
exogenous glucose delivery on energy production
while monitoring total carbon dioxide produc-
tion, protein synthesis, and amount of insulin
required to keep glucose toward normal range.65
They found that there was a maximal rate of
glucose infusion beyond which physiologically
significant increases in protein synthesis and
direct oxidation of glucose cannot be expected.
Carbon dioxide production from glucose oxidation
reached a plateau at greater than 5 mg/kg/minute,
insulin did not increase glucose oxidation, and
no significant difference was noted with protein
synthesis among high (4.7–6.8 mg/kg/min), very
high (7–9.3 mg/kg/min), and low (1.4–4.5
mg/kg/min) glucose infusions.  Furthermore, if
the optimum glucose infusion rate was exceeded,
an increase occurred in the rate of carbon dioxide
production from fat synthesis, resulting in large
lipid deposits in the liver.
In 1980, another group studied the correlation
between glucose clearance and glucose oxidation
during administration of parenteral nutrition in a
small population of postoperative nearly healthy
subjects.66 They showed no significant increase
in blood glucose level when the dextrose infusion
rate was increased from 4 to 7–9 mg/kg/minute.
However, there was a limit to the ability to derive
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energy from infused glucose and thus a
questionable benefit derived from a dextrose
infusion rate of 6–7 mg/kg/minute with potential
detrimental effects of glucose overdose.
A retrospective study was performed to deter-
mine whether the frequency of hyperglycemia
(blood glucose level > 200 mg/dl) increased in
patients not predisposed to hyperglycemia who
received parenteral nutrition in excess of 4–5
mg/kg/minute.67 Results showed a positive
correlation between parenteral nutrition dextrose
infusion rate and blood glucose level; thus, the
authors concluded that exceeding a dextrose
infusion rate of 4–5 mg/kg/minute increases the
risk of hyperglycemia.
Substituting a portion of the dextrose calories
with lipids in parenteral nutrition helps control
the hyperglycemia.  Normally, 20–30% of total
daily calories are provided as lipids.  Increasing
lipid intake beyond these levels to substitute for
dextrose calories may not be desirable.  This is
due to concerns of possible fat immunosuppres-
sive effects through reduction of cytokine
secretion and inhibition of phagocytosis.68 In
addition, insulin therapy should be started as
necessary for glucose control.
Historically, in a patient with hyperglycemia
who is receiving parenteral nutrition (blood
glucose target 150–200 mg/dl), sliding scale
insulin would be started for 1–2 days, then the
average of the 24-hour insulin requirements
would be calculated; 70% of that would be
included in the parenteral nutrition bag (with no
less than 10 U/bag) while continuing to monitor
insulin requirements and adjusting accordingly.
However, using subcutaneous sliding scale
insulin therapy may leave patients hyperglycemic
for prolonged periods of time.  Also, adding
insulin to parenteral nutrition does not allow
flexible titration of the insulin dosage based on
blood glucose levels.  As such, maintaining tight
glucose control in hyperglycemic critically ill
patients is best achieved with continuous insulin
infusion.
In 1987, one group evaluated the efficacy, safety,
and cost-effectiveness of treating parenteral
nutrition–induced hyperglycemia with a continu-
ous insulin infusion separate from the parenteral
nutrition and showed that it was a safe, effective,
cost-effective and more flexible way of control-
ling parenteral nutrition–induced hyperglycemia.69
After publication of the 2001 study,20 there is
less tolerance for hyperglycemia, and continuous
insulin infusion is preferred over sliding scale
insulin.
Insulin Infusions
As data continue to accumulate, the role of
continuous insulin infusions in the ICU will
likely be increasing.  Available evidence supports
the use of strict glycemic control in surgical
patients, although published guidelines vary
regarding selection of patients and level of
glycemic control.70, 71 Use of an algorithm
provides an easy mechanism for improved
glycemic control in patients in the ICU (Table 2).
Any algorithm for glucose control should have a
degree of flexibility to accommodate the clinical
condition of each patient.  Numerous factors
contribute to a patient’s hyperglycemia and the
corresponding insulin requirements for control,
including insulin production reserves, insulin
sensitivity, caloric intake, severity of illness,
presence of infection, and use of certain drugs
(e.g., corticosteroids).72 Insulin dosage
adjustments should be proportionate to the rate
of change of serum glucose concentration.  Thus,
a serum glucose concentration of 250 mg/dl may
or may not require a change in the insulin
dosage, depending on the preceding glucose
concentration.  Further, it should be expected
that after normoglycemia is achieved, the need
for monitoring glucose and adjusting the insulin
dosage remains.  As patients improve (or
deteriorate), insulin sensitivity is expected to
change, leading to changes in insulin require-
ments.  Finally, insulin infusions should be inter-
rupted whenever nutrition support is interrupted.
Use of continuous insulin infusions enables
rapid glycemic control.  However, more intensive
monitoring is required to minimize risk of hypo-
glycemia, thus potentially straining personnel
resources.  As institutions move to adopt some
form of intensive insulin therapy for critically ill
patients, the level of glycemic control in the
context of existing resources must be carefully
evaluated.  However, apart from reducing sepsis-
related mortality, the dramatic reduction in
morbidity associated with intensive insulin
therapy should be fully appreciated.  For
example, intensive insulin therapy decreased the
frequency of new-onset renal failure requiring
dialysis by 41%.20 Generally, patients receiving
continuous renal replacement therapy require 1:1
nursing care.  Thus, the decreased frequency of
renal failure associated with intensive insulin
therapy would be associated with significant
resource savings.  A full cost-benefit analysis
seems warranted.
Although the safety and efficacy of insulin
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nomograms had been demonstrated73 before
publication of the 2001 study,20 the frequency of
hypoglycemia in critically ill patients had not
been described at the goal blood glucose level of
80–110 mg/dl.  In the 2001 study,20 patients
received a mean insulin infusion rate of 0.04
IU/kg/hour with a mean dextrose administration
rate of 9 g/hour.  Hypoglycemia, defined as a
blood glucose level below 40 mg/dl, occurred
more in the intensive treatment group than in the
conventional group (5.2% vs 0.8%).  The authors
noted that the episodes of hypoglycemia were
largely a result of human error, which could be
avoided with increased experience.  Furthermore,
none of the hypoglycemic episodes that occurred
led to serious adverse events.20, 26
Conclusion
Available evidence has established the risk of
morbidity and mortality secondary to infection
related to hyperglycemia.  Hyperglycemia results
in impaired host defenses, increasing the risk for
infection in the critically ill.  Use of intensive
insulin therapy has been shown to significantly
decrease infectious complications in selected
patient populations, perhaps through modulation
of inflammatory mediators and minimization of
impairment of host defense mechanisms.
Further research will refine those patient
populations that are most likely to benefit from
intensive insulin therapy.
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